更新于：2024-11-01

KIF20B

更新于：2024-11-01

基本信息

别名

Cancer/testis antigen 90、CT90、KIF20B

+ [7]

简介

Plus-end-directed motor enzyme that is required for completion of cytokinesis (PubMed:11470801, PubMed:12740395). Required for proper midbody organization and abscission in polarized cortical stem cells. Plays a role in the regulation of neuronal polarization by mediating the transport of specific cargos. Participates in the mobilization of SHTN1 and in the accumulation of PIP3 in the growth cone of primary hippocampal neurons in a tubulin and actin-dependent manner. In the developing telencephalon, cooperates with SHTN1 to promote both the transition from the multipolar to the bipolar stage and the radial migration of cortical neurons from the ventricular zone toward the superficial layer of the neocortex. Involved in cerebral cortex growth (By similarity). Acts as an oncogene for promoting bladder cancer cells proliferation, apoptosis inhibition and carcinogenic progression (PubMed:17409436).

关联

项与 KIF20B 相关的药物

Asudemotide

靶点

DEPDC1 x IGF2BP3 x KIF20B x LY6K x NUF2

作用机制

DEPDC1抑制剂 [+4]

在研机构

OncoTherapy Science, Inc. [+1]

原研机构

OncoTherapy Science, Inc.

在研适应症

食管癌 [+2]

非在研适应症-

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期1800-01-20

项与 KIF20B 相关的临床试验

JPRN-UMIN000023324 / Completed临床1期

Exploratory study to determine S-588410-induced tumor infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients - Exploratory study to determine S-588410-induced tumor infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients

开始日期2016-07-25

申办/合作机构

Shionogi & Co., Ltd.

JPRN-UMIN000016954 / Completed临床3期

A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of S-588410 as adjuvant therapy after curative resection in patients with esophageal cancer - A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of S-588410 as adjuvant therapy after curative resection in patients with esophageal cancer

开始日期2015-05-01

申办/合作机构

Shionogi & Co., Ltd.

NCT02410369 / Unknown status临床2期IIT

Phase II Study of S-588410 as Maintenance Monotherapy After Adjuvant Chemotherapy in Patients With Completely Resected Non-small- Cell Lung Cancer

In this clinical study, the investigators evaluate the efficacy and safety of S-588410 in patients who underwent an adjuvant chemotherapy after the complete resection of non-small-cell lung cancer.

开始日期2015-03-01

申办/合作机构

University of Tokyo

[+5]

100 项与 KIF20B 相关的临床结果

登录后查看更多信息

100 项与 KIF20B 相关的转化医学

登录后查看更多信息

0 项与 KIF20B 相关的专利（医药）

登录后查看更多信息

项与 KIF20B 相关的文献（医药）

2024-11-01·Biochemical and Biophysical Research Communications

Comprehensive proteomics analysis reveals novel Nek2-regulated pathways and therapeutic targets in cancer

Article

作者: Cicek, Enes ; Baykal, Ahmet Tarik ; Ayhan, Ceyda Acilan ; Kalkan, Batuhan Mert ; Acilan, Ceyda

The mitotic kinase Nek2, often overexpressed in various cancers, plays a pivotal role in key cellular processes like the cell cycle, proliferation, and drug resistance. As a result, targeting Nek2 has become an appealing strategy for cancer therapy. To gain a comprehensive understanding of the cellular changes associated with Nek2 activity modulation, we performed a global proteomics analysis using LC-MS/MS. Through bioinformatics tools, we identified molecular pathways that are differentially regulated in cancer cells with Nek2 overexpression or depletion. Of the 1815 proteins identified, 358 exceeded the 20 % significance threshold. By integrating LC-MS/MS data with cancer patient datasets, we observed a strong correlation between Nek2 expression and the levels of KIF20B and RRM1. Silencing Nek2 led to a significant reduction in KIF20B and RRM1 protein levels, and potential phosphorylation sites for these proteins by Nek2 were identified. In summary, our data suggests that KIF20B and RRM1 are promising therapeutic targets, either independently or alongside Nek2 inhibitors, to improve clinical outcomes. Further analyses are necessary to fully understand Nek2's interactions with these proteins and their clinical relevance.

2024-04-01·Lupus Science & Medicine

Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus

Article

作者: Krustev, Eugene ; Jönsen, Andreas ; Fritzler, Marvin J ; Ruiz-Irastorza, Guillermo ; Ginzler, Ellen M ; Mackay, Meggan ; van Vollenhoven, Ronald F ; Inanc, Murat ; Gordon, Caroline ; Hanly, John G ; Petri, Michelle A ; Clarke, Ann E ; Manzi, Susan ; Gladman, Dafna D ; Kalunian, Kenneth C ; Urowitz, Murray B ; Chin, Ricky ; Merrill, Joan T ; Isenberg, David ; Askenase, Anca ; Dooley, Mary Anne ; Jacobsen, Søren ; Fortin, Paul R ; Wallace, Daniel J ; Buyon, Jill ; Kamen, Diane L ; Choi, May Y ; Bernatsky, Sasha ; Peschken, Christine A ; Sánchez-Guerrero, Jorge ; Bruce, Ian N ; Alarcón, Graciela S ; Lim, Sam ; Romero-Diaz, Juanita ; Aranow, Cynthia ; Bae, Sang-Cheol ; Ramsey-Goldman, Rosalind ; Rahman, Anisur ; Buhler, Katherine A

BackgroundCranial neuropathies (CN) are a rare neuropsychiatric SLE (NPSLE) manifestation. Previous studies reported that antibodies to the kinesin family member 20B (KIF20B) (anti-KIF20B) protein were associated with idiopathic ataxia and CN. We assessed anti-KIF20B as a potential biomarker for NPSLE in an international SLE inception cohort.MethodsIndividuals fulfilling the revised 1997 American College of Rheumatology (ACR) SLE classification criteria were enrolled from 31 centres from 1999 to 2011 and followed annually in the Systemic Lupus Erythematosus International Collaborating Clinics inception cohort. Anti-KIF20B testing was performed on baseline (within 15 months of diagnosis or first annual visit) samples using an addressable laser bead immunoassay. Logistic regression (penalised maximum likelihood and adjusting for confounding variables) examined the association between anti-KIF20B and NPSLE manifestations (1999 ACR case definitions), including CN, occurring over the first 5 years of follow-up.ResultsOf the 1827 enrolled cohort members, baseline serum and 5 years of follow-up data were available on 795 patients who were included in this study: 29.8% were anti-KIF20B-positive, 88.7% female, and 52.1% White. The frequency of anti-KIF20B positivity differed only for those with CN (n=10) versus without CN (n=785) (70.0% vs 29.3%; OR 5.2, 95% CI 1.4, 18.5). Compared with patients without CN, patients with CN were more likely to fulfil the ACR haematological (90.0% vs 66.1%; difference 23.9%, 95% CI 5.0%, 42.8%) and ANA (100% vs 95.7%; difference 4.3%, 95% CI 2.9%, 5.8%) criteria. In the multivariate analysis adjusting for age at baseline, female, White race and ethnicity, and ACR haematological and ANA criteria, anti-KIF20B positivity remained associated with CN (OR 5.2, 95% CI 1.4, 19.1).ConclusionAnti-KIF20B is a potential biomarker for SLE-related CN. Further studies are needed to examine how autoantibodies against KIF20B, which is variably expressed in a variety of neurological cells, contribute to disease pathogenesis.

2024-02-01·Pathology - Research and Practice

KIF20B and MET, hub genes of DIAPHs, predict poor prognosis and promote pancreatic cancer progression

Article

作者: Ruan, Linjie ; Cheng, Chienshan ; Guan, Mingwei ; Chen, Zhen ; Zhang, Ke ; Jing, Yanhua ; Jiao, Juying ; Wang, Fengjiao ; Cao, Zhangqi

BACKGROUNDThe DIAPHs (DIAPH1, DIAPH2, and DIAPH3) are members of the diaphanous subfamily of the formin family. KIF20B and MET, hub genes of DIAPHs, play crucial roles in cytoskeletal remodeling, cell migration, and adhesion. However, their combined prognostic and treatment value in pancreatic adenocarcinoma (PC) warrants further investigation.METHODSMultiomics analysis tools were used to comprehensively assess the genomic expression and prognostic value of KIF20B and MET in PC. Immune cell infiltration, functional enrichment, single-cell RNA-seq (scRNA) analysis, potential therapeutic drugs, and nomograms were established and analyzed. CCK-8 levels, transwell assay, Co-IP assay, mass spectrometry, and western blotting were performed to assess the role of KIF20B and MET as modulators of β-catenin and Lactate Dehydrogenase A (LDHA) in vitro. Xenograft tumor models were used to evaluate the anti-tumor effects in vivo.RESULTSDIAPHs, KIF20B, and MET were overexpressed and functioned as poor prognostic markers of PC. Immunoinfiltration analysis revealed that pDC and NK cells were enriched with low expression levels of KIF20B and MET, whereas Th2 cells were enriched with high expression levels of these two genes. The copy number variations (CNVs) in KIF20B and MET were positively correlated with B cell and CD4 + T cell infiltration. Immunological checkpoints NT5E and CD44 were positively correlated with KIF20B and MET expression. Moreover, the nomogram constructed based on KIF20B and MET demonstrated predictive value for overall survival. scRNA-Seq analysis indicated that KIF20B and MET were enriched in endothelial, malignant, B, T, and CD8 + T cells, which correlated with glycolysis and the epithelial-mesenchymal transition (EMT). The interactions of KIF20B and MET with β-catenin and LDHA were verified by Co-IP assay and mass spectrometry. Knockdown of KIF20B and MET downregulates β-catenin and LDHA in vitro. Furthermore, dual knockdown of KIF20B and MET exhibited a synergistic suppressive effect on PC progression in vitro and in vivo.CONCLUSIONDIAPHs, KIF20B, and MET are promising candidates for the prognosis and treatment of PC. More importantly, downregulation of KIF20B and MET inhibited pancreatic cancer progression by regulating LDHA and EMT.